CBIO
Crescent Biopharma, Inc.
There isn't enough reported data to score CBIO yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
CBIO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CBIO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CBIO PE Valuation
CBIO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CBIO's losses to shrink, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$17.88 | +$44.12 |
| Q2 2025 | -$31.37 | +$29.63 |
| Q1 2025 | -$46.00 | +$12.00 |
| Q4 2024 | -$59.00 | -$1.00 |
| Q3 2024 | -$62.00 | +$2.00 |
| Q2 2024 | -$61.00 | +$5.00 |
| Q1 2024 | -$58.00 | +$20.00 |
| Q4 2023 | -$58.00 | +$31.00 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 129% for CBIO versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
CBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $75K | +52717% |
| Q4 2021 | $17.6K | -89% |
| Q3 2021 | $86.6K | -91% |
| Q1 2021 | $1.1M | -88% |
CBIO's revenue is growing: $3M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1280% | N/A |
| Q1 2026 | -2380% | N/A |
| Q2 2022 | -17804% | +10126197 points |
| Q4 2021 | -98870% | -89315 points |
| Q3 2021 | -20029% | -18656 points |
| Q2 2021 | -10144001% | N/A |
| Q1 2021 | -1353% | -1263 points |
| Q4 2020 | -9555% | N/A |
CBIO's operating margin was −1280% last quarter, up 18749 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CBIO on profitability, with a higher operating margin.
CBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.9M | -$8.8M |
| Q4 2025 | -$26.9M | -$23.2M |
| Q3 2025 | -$18.1M | -$10.1M |
| Q4 2024 | -$3.7M | +$3.9M |
| Q3 2024 | -$8M | +$696.7K |
| Q2 2024 | -$8.9M | -$1.9M |
| Q1 2024 | -$10.5M | +$1.1M |
| Q4 2023 | -$7.6M | +$295.8K |
CBIO has burned cash in almost every quarter: −$82M over the past year, against −$39M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over CBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +1.8M shares |
| 1 year | +180% | +25M shares |
| 3 years | +5944% | +38.3M shares |
| 5 years | +7443% | +38.4M shares |
| Available history | +8892% | +38.5M shares |
CBIO has 39M diluted shares, up 180% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over CBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CBIO Net Leverage
CBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
CBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.5 | Neutral |
| Stochastic | 19.1 | Oversold |
CBIO's weekly RSI is 46 (neutral) and its Stochastic is 19 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CBIO PE vs Healthcare Sector
CBIO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 5.2% above |
| 20 week MA | $15.8 | 8.8% below |
| 50 week MA | $15.4 | 6.7% below |
| 100 week MA | $17.3 | 17% below |
| 200 week MA | $80.5 | 82% below |
CBIO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 82% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CBIO on trend strength, trading above more of its moving averages.
CBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $570.0 | $412.0 | -28% |
| 2021 | $412.0 | $160.0 | -61% |
| 2022 | $160.0 | $227.0 | +42% |
| 2023 | $227.0 | $236.0 | +4% |
| 2024 | $236.0 | $23.6 | -90% |
| 2025 | $23.6 | $12.4 | -48% |
| 2026 YTD | $12.4 | $14.4 | +16% |
CBIO has finished lower in four of the last six years. It's up 16% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CBIO on returns for 2026, with the stronger performance.